Docetaxel plus ramucirumab (DR) versus docetaxel plus placebo (D) as second-line treatment for advanced non-small cell lung cancer (NSCLC): A randomized, phase II, double-blind, multicenter trial in Japan.

被引：0
|
作者：
Hosomi, Yukio
Yoh, Kiyotaka
Kasahara, Kazuo
Yamada, Kazuhiko
Takahashi, Toshiaki
Tanaka, Kaoru
Hida, Toyoaki
Yoshioka, Hiroshige
Kato, Terufumi
Takeda, Koji
Nishio, Makoto
Sakai, Hiroshi
Maemondo, Makoto
Takenoyama, Mitsuhiro
Nokihara, Hiroshi
Tatsumi, Masumi
Nakamura, Takashi
Enatsu, Sotaro
Tamura, Tomohide
Nakagawa, Kazuhiko
机构：
[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[2] Natl Canc Ctr Hosp East, Div Thorac Oncol, Kashiwa, Chiba, Japan
[3] Kanazawa Univ, Grad Sch Med Sci, Dept Resp Med, Cellular Transplantat Biol, Kanazawa, Ishikawa, Japan
[4] Kurume Univ, Sch Med, Kurume, Fukuoka 830, Japan
[5] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan
[6] Kiniki Univ, Fac Med, Osaka, Japan
[7] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi 464, Japan
[8] Kurashiki Cent Hosp, Kurashiki, Okayama, Japan
[9] Kanagawa Cardiovasc & Resp Ctr, Yokohama, Kanagawa, Japan
[10] Osaka City Gen Hosp, Dept Clin Oncol, Osaka, Japan
[11] Japanese Fdn Canc Res, Tokyo, Japan
[12] Saitama Canc Ctr, Saitama, Japan
[13] Miyagi Canc Ctr, Sendai, Miyagi, Japan
[14] Kyushu Canc Ctr, Natl Hosp Org, Fukuoka, Japan
[15] Natl Canc Ctr, Tokyo, Japan
[16] Eli Lilly Japan, Kobe, Hyogo, Japan
[17] Lilly Res Labs Japan, Kobe, Hyogo, Japan
[18] St Lukes Int Hosp, Tokyo, Japan
[19] Kinki Univ, Fac Med, Osakasayama, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8054
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Docetaxel (D) versus docetaxel plus gemcitabine (DG) for second-line treatment of non-small cell lung cancer (NSCLC): Results of a JCOG randomized trial (JCOG0104).
    Takeda, K
    Negoro, S
    Tamura, T
    Nishiwaki, Y
    Kudoh, S
    Fukuda, H
    Saijo, N
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 625S - 625S
  • [12] Anlotinib plus docetaxel versus docetaxel as second-line treatment for advanced non-small cell lung cancer (NSCLC): Updated results from a phase I/II study.
    Fang, Yong
    Pan, Hongming
    Shou, Jiawei
    Hong, Wei
    Guo, Qunyi
    Yang, Xinmei
    Zhu, Dan
    Chen, Jun
    Lu, Liqin
    Rao, Chuangzhou
    Lan, Fen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [13] Exposure-response relationship for ramucirumab (RAM) from the randomized, double-blind, phase 3 REVEL trial (docetaxel [DOC] plus placebo [PL] vs DOC plus RAM) in second-line treatment of metastatic non-small cell lung cancer (NSCLC)
    Reck, M.
    Smit, E.
    Garon, E. B.
    Cappuzzo, F.
    Bidoli, P.
    Cohen, R.
    Gao, L.
    Ernest, C. S., II
    Lee, P.
    Zimmermann, A.
    Ferry, D.
    Treat, J.
    Melemed, A.
    Perol, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 119 - 119
  • [14] Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: A randomized, multicenter phase III trial
    Georgoulias, Vassilis
    Androulakis, Nikolaos
    Kotsakis, Athanasios
    Hatzidaki, Dora
    Syrigos, Kostas
    Polyzos, Aris
    Agelidou, Athina
    Varthalitis, Loannis
    Ziras, Nikoalos
    Agelidou, Maria
    Chandrinos, Vassilis
    Boukovinas, Loannis
    Geroyianni, Alexandra
    Vamakas, Larnbros
    Mavroudis, Dirnitris
    LUNG CANCER, 2008, 59 (01) : 57 - 63
  • [15] Updated results from a phase I/II study of anlotinib plus docetaxel vs docetaxel as second-line treatment of advanced non-small cell lung cancer (NSCLC)
    Fang, Y.
    Pan, H.
    Shou, J.
    Hong, W.
    Chen, J.
    Wang, Y.
    Guo, Q.
    Lu, L.
    Rao, C.
    Yang, X.
    Zhu, D.
    Lan, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1021 - S1021
  • [16] Phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC)
    Leighl, N
    Laurie, S
    Knox, J
    Ellis, P
    Shepherd, F
    Burkes, R
    Pond, G
    Zwiebel, J
    Moore, M
    LUNG CANCER, 2005, 49 : S256 - S256
  • [17] Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
    Garon, Edward B.
    Ciuleanu, Tudor-Eliade
    Arrieta, Oscar
    Prabhash, Kumar
    Syrigos, Konstantinos N.
    Goksel, Tuncay
    Park, Keunchil
    Gorbunova, Vera
    Dario Kowalyszyn, Ruben
    Pikiel, Joanna
    Czyzewicz, Grzegorz
    Orlov, Sergey V.
    Lewanski, Conrad R.
    Thomas, Michael
    Bidoli, Paolo
    Dakhil, Shaker
    Gans, Steven
    Kim, Joo-Hang
    Grigorescu, Alexandru
    Karaseva, Nina
    Reck, Martin
    Cappuzzo, Federico
    Alexandris, Ekaterine
    Sashegyi, Andreas
    Yurasov, Sergey
    Perol, Maurice
    LANCET, 2014, 384 (9944): : 665 - 673
  • [18] Investigation of response of patients with non-small cell lung cancer to docetaxel (plus ramucirumab) therapy in second-line treatment
    Takahara, Yutaka
    Abe, Ryudai
    Nagae, Sumito
    Tanaka, Takuya
    Ishige, Yoko
    Shionoya, Ikuyo
    Yamamura, Kouichi
    Nishiki, Kazuaki
    Nojiri, Masafumi
    Kato, Ryo
    Shinomiya, Shohei
    Oikawa, Taku
    THORACIC CANCER, 2023, 14 (36) : 3549 - 3555
  • [19] Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer
    Ready, Neal
    Karaseva, Nina A.
    Orlov, Sergey V.
    Luft, Alexander V.
    Popovych, Olexandr
    Holmlund, Jon T.
    Wood, Brian A.
    Leopold, Lance
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (04) : 781 - 785
  • [20] Weekly docetaxel as a second-line treatment for advanced non-small cell lung cancer (NSCLC).
    García, R
    Pérez, P
    Alfonso, R
    Pérez-Manga, G
    Díaz-Rubio, E
    ANNALS OF ONCOLOGY, 2000, 11 : 116 - 116
12345